穿皮冠状动脉干预 (ATPCI) 后的三甲的有效性和安全性:一个随机,双盲,安慰剂对照的试验
Roberto Ferrari1, Ian Ford2, Kim Fox3
1Cardiovascular Centre, University of Ferrara, Ospedale di Cona, Ferrara, Italy; Maria Cecilia Hospital, Cotignola, Ravenna, Italy.
Lancet (London, England)
|September 3, 2020
概括
在皮肤冠状动脉干预 (PCI) 后,trimetazidine没有显著减少心痛复发或改善患者的结果. 长期使用trimetazidine被认为是安全的,没有发现重大安全问题.
科学领域:
- 心脏病学
- 药理学
背景情况:
- 经皮肤冠状动脉干预 (PCI) 后,心痛可能会持续.
- 三甲是一种抗血管剂,向心肌能量代谢.
- 这项研究研究了三甲在PCI后患者的长期影响.
研究的目的:
- 评估在PCI成功后患者的标准医疗治疗中添加的三甲的长期益处和安全性.
主要方法:
- 这是一项随机,双盲,安慰剂对照的试验,
- 在标准治疗中,患者接受了三甲 (每天两次35毫克) 或安慰剂.
- 主要终点是心脏病死亡,心脏病住院或心痛复发的综合结果.
主要成果:
- 在trimetazidine和安慰剂组之间没有观察到主要终点的显著差异 (23. 3% vs 23. 7%).
- 主要终点的各个组成部分也没有显著差异.
- 治疗出现的严重不良事件在各组之间是相似的,表明可比的安全性.
结论:
- 在成功的PCI后,常规的长期使用trimetazidine似乎没有影响心痛的复发或患者的结果.
- 这项研究表明,在这种患者群体中,除了最佳的药物治疗之外,三甲没有显著的益处.
- 在PCI后的患者中,长期处方trimetazidine没有显示出统计学上显著的安全问题.
更多相关视频
08:33Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
Published on: January 5, 2024
1.5K
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
4.1K
相关概念视频
Acute Coronary Syndrome IV: Interprofessional Care
134
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
134
Peripheral Artery Disease III: Interprofessional Care
157
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
157
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.1K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.1K
